Nucleoside and nucleotide reverse transcriptase inhibitors in children

Clinical Drug Investigation

Volumn 27, Issue 8, 2007, Pages 509-531

  Giaquinto, Carlo ^a   Rampon, Osvalda ^a   Penazzato, Martina ^a   Fregonese, Federica ^a   De Rossi, Anita ^a   D'Elia, Ruggiero ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; EPIZICOM; GPOVIRZ; INDINAVIR; LAMIVIR BABY; LAMIVIR JUNIOR; LAMIVIR S; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PEDIMMUNE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; TRIOMMUNE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTHRALGIA; BONE DEMINERALIZATION; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CEREBROSPINAL FLUID; CHILD; COUGHING; DEATH; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; LACTIC ACIDOSIS; LEUKOPENIA; LIPOATROPHY; LIPODYSTROPHY; LIVER DYSFUNCTION; LONG TERM CARE; LYMPHOCYTOPENIA; MACROCYTIC ANEMIA; MACULOPAPULAR RASH; MITOCHONDRIAL TOXICITY; MONOTHERAPY; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RASH; RETINA DISEASE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STEATOSIS; THROMBOCYTOPENIA; URTICARIA; VERTICAL TRANSMISSION; VIRUS MUTATION; VOMITING; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; NUCLEOSIDES; NUCLEOTIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34547173254     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727080-00001     Document Type: Review

References (136)

1. UNAIDS/WHO AIDS epidemic update: December 2006 [online]. Available from URL: http://www.unaids.org/en/HIV_data/epi2006/default.asp [Accessed 2007 Feb 13]
2. Progress on global access to HIV antiretroviral therapy: a report on '3 by 5' and beyond [online]. Available from URL: http://www.who.int/hiv/ progreport2006_summary_en.pdf [Accessed 2007 Feb 14]
3. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998 Mar 11; 279 (10): 756-61
4. de Martino M, Tovo PA, Galli L, et al. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS 2001 Aug 17; 15 (12): 1527-34
5. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001 Nov 22; 345 (21): 1522-8
6. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998 Mar 26; 338 (13): 853-60
7. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach [online]. Available from URL: http://www.who.int/hiv/pub/ guidelines/art/en/index.htm [Accessed 2007 Feb 13]
8. Sharland M, Gibb D, Giaquinto C, et al. A PENTA analysis. Eur J Pediatr 2000; 159 (9): 649-56
9. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999 May 27; 340 (21): 1605-13
10. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis 1996 Jul; 174 (1): 16-25
11. Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-different infected children. AIDS Clinical Group (ACTG) Study 152 Team. N Engl J Med 1997 Jun 12; 336 (24): 1704-12
12. McKinney Jr RE, Johnson BM, Stanley K, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr 1998 Oct; 133 (4): 500-8
13. Paediatric European Network for Treatment of AIDS. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. AIDS 1998 Oct 1; 12 (14): F151-60
14. Kline MW, Van Dyke RB, Lindsey JC, et al. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trial Group 240 Team. Pediatrics 1998 Feb; 101 (2): 214-20
15. Stretcher BN. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Clin Pharmacokinet 1995 Jul; 29 (1): 46-65
16. Gao WY, Shirasaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993 May; 91 (5): 2326-33
17. Ingrand D, Weber J, Boucher CA, et al. Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group. AIDS 1995 Dec; 9 (12): 1323-9
18. Handforth J, Sharland M. Triple nucleoside reverse transcriptase inhibitor therapy in children. Paediatr Drugs 2004; 6 (3): 1-14
19. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994 Apr 9; 343 (8902): 871-81
20. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatrics AIDS Clinical Trial Group Protocol 076 Study Group. N Engl J Med 1994 Nov 3; 331 (18): 1173-80
21. Wintergerst U, Rolinski B, Vocks-Hauck M, et al. Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. Infection 1995 Nov-Dec; 23 (6): 344-8
22. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988; 319 (14): 889-96
23. Mueller BU, Pizzo PA, Farley M, et al. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr 1994; 125 (1): 142-6
24. Bakshi SS, Britto P, Capparelli E, et al. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection tion. AIDS Clinical Trials Group Protocol 190 Team. J Infect Dis 1997; 175 (5): 1039-50
25. Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin Pharmacol Ther 1999 Jul; 66 (1): 16-24
26. Mirochnick M, Capparelli E, Dankner W, et al. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimicrob Agents Chemother 1998; 42 (4): 808-12
27. The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection, October 26, 2006 [online]. Available from URL: http://www.aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf [Accessed 2007 Feb 14]
28. Capparelli EV, Letendre SL, Ellis RJ, et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2005 Jun; 49 (6): 2504-6
29. Mueller BU, Lewis LL, Yuen GJ, et al. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 1998 Dec; 42 (12): 3187-92
30. Fraaij PLA, van Kampen JA, Burger D, et al. Pharmacokinetics of antiviral therapy in HIV-1 infected children. Clin Pharmacokinet 2005; 44 (9): 935-56
31. McKinney Jr RE, Mahal MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The protocol 043 Study Group. N Engl J Med 1991 Apr 11; 324 (15): 1018-25
32. Sharland M, Blanche S, Castelli G, et al. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004 Jul; 5 Suppl. 2: 61-86
33. King JR, Nachman S, Yogev R, et al. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children. Antivir Ther 2002 Dec; 7 (4): 267-70
34. Stevens RC, Rodman JH, Yong FH, et al. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. AIDS Res Hum Retroviruses 2000 Mar 20; 16 (5): 415-21
35. Abreu T, Plaisance K, Rexroad V, et al. Bioavailability of once-and twice-daily regimens of didanosine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2000 May; 44 (5): 1375-6
36. Balis FM, Pizzo PA, Butler KM, et al. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992 Jan; 165 (1): 99-104
37. Whitcup SM, Butler KM, Caruso R, et al. Retinal toxicity in human immunodeficiency virus-infected children treated with 2′,3′- dideoxyinosine. Am J Ophthalmol 1992 Jan 15; 113 (1): 1-7
38. Butler KM, Venzon D, Henry N, et al. Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine. Pediatrics 1993 Apr; 91 (4): 747-51
39. M.D./alert® . Dear health care professional [online]. Available from URL: http://www.fda.gov/cder/drug/shortages/Roche_HIVID_MDLetter.pdf [Accessed 2007 Feb 15]
40. Chadwick EG, Nazareno LA, Nieuwenhuis TJ, et al. Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children. J Infect Dis 1995 Dec; 172 (6): 1475-9
41. Bakshi SS, Britto P, Capparelli E, et al. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. J Infect Dis 1997 May; 175 (5): 1039-50
42. Viani RM, Smith IL, Spector SA. Human immunodeficiency virus type 1 phenotypes in children with advanced disease treated with long-term zalcitabine. J Infect Dis 1998 Mar; 177 (3): 565-70
43. Gibb DM, Carrìere I, Giaquinto C, et al. The safety and tolerability of zidovudine (ZDV) and zalcitabine (ddC) in children with symptomatic HIV infection: PENTA 3 [abstract]. VIth European Conference on Clinical Aspects and Treatment of HIV-Infection; 1997 Oct 1-15; Hamburg
44. B Gazzard, on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Medicine 2006; 7: 487-503
45. King JR, Kimberlin DW, Aldrovandi GM, et al. Antiretroviral pharmacokinetics in the paediatric population: a review. Clin Pharmacokinet 2002; 41 (14): 1115-33
46. Sokal EM, Roberts EA, Mieli-Vergani G, et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000 Mar; 44 (3): 590-7
47. Moodley D, Pillay K, Naidoo K, et al. Pharmacokinetics of zidovudine and lamivudine in neonates following co-administration of oral doses every 12 hours. J Clin Pharmacol 2001 Jul; 41 (7): 732-41
48. Bergshoeff A, Burger D, Verweij C, et al. Pharmacokinetics of once versus twice daily lamivudine and abacavir: simplification of combination treatment in HIV-1 infected children. Antivir Ther 2005; 10 (2): 239-46
49. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22 (6): 685-708
50. Kaul S, Kline MW, Church JA, et al. Determination of dosing guidelines for stavudine (2′,3′-didehydro-3′-deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 2001 Mar; 45 (3): 758-63
51. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) children with human immunodeficiency virus infection. Pediatrics 1995 Aug; 96 (2 Pt 1): 247-52
52. Kline MW, Fletcher CV, Harris AT, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr 1998 Mar; 132 (3 Pt 1): 543-6
53. Kline MW, Fletcher CV, Federici ME, et al. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 1996 Jun; 97 (6 Pt 1): 886-90
54. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002 Dec 6. 16 (18): 2447-54
55. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004 Jul 2; 18 (10): 1443-51
56. Scherpbier HJ, Bekker V, van Leth F, et al. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics 2006 Mar; 117 (3): e528-36
57. Saez-Llorens X, Nelson Jr RP, Emmanuel P, et al. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. Pediatrics 2001 Jan; 107 (1): E4
58. Daluge SM, Good SS, Faletto MB, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human human immunodeficiency virus activity. Antimicrob Agents Chemother 1997 May; 41 (5): 1082-93
59. Paediatric European Network for Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 2007; 21: 947-55
60. Fatal hypersensitivity reactions, respiratory symptoms, and Ziagen® (abacavir sulfate) [online]. Available from URL: http://www.fda.gov/medwAtch/ sAfety/2000/ziagen.htm [Accessed 2007 Feb 14]
61. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001 Oct; 23 (10): 1603-14
62. Hughes W, McDowell JA, Shenep J, et al. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrobial Agents Chemother 1999 Mar; 43 (3): 609-15
63. Kline MW, Blanchard S, Fletcher CV, et al. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. Pediatrics 1999 Apr; 103 (4): e47
64. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002 Mar; 46 (3): 716-23
65. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis 2002 Apr 15; 34 (8): 1137-42
66. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002 Mar 30; 359 (9312): 1121-2
67. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002 Mar 2; 359 (9308): 727-32
68. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004 Jun; 14 (6): 335-42
69. Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002 Apr; 24 (4): 565-73
70. Gibb DM, Melvin A, Compagnucci A, et al. Choice of first-line ART regimen in PENPACT-1: a randomized trial of combination antiretroviral regimens and treatment switching strategies in antiretroviral naive children >30 days and <18 years of age [poster TuPeB4442]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
71. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 2005; 10 Suppl. 2: M47-52
72. Stekler J, Maenza J, Stevens C, et al. Abacavir hypersensitivity reaction in primary HIV infection. AIDS 2006 Jun 12; 20 (9): 1269-74
73. Gazzard B, G Moyle, M Nelson, et al. The combination of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) has significantly greater response vs. fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naive patients: a 24 week preliminary analysis [abstract no. H1137c]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
74. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004 Jan; 48 (1): 124-9
75. Kearney B, Abadi J, Rosenberg M, et al. Pharmacokinetics of tenofovir DF oral suspension in HIV-1-infected children between 2 and 8 years of age [abstract no. N935]. 11th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 8-11; San Francisco (CA)
76. Tung MY, Mandalia S, Bower M, et al. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily. HIV Med 2005 May; 6 (3): 151-4
77. Gafni R, Hazra R, Reynolds J, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006 Sep; 118 (3): e711-8
78. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for paediatric HIV infection. Pediatrics 2005 Dec; 116 (6): e846-54
79. Vigano A, Aldrovandi GM, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther 2005; 10 (8): 917-24
80. Schinazi RF. Assessment of the relative potency of emtricitabine and lamivudine. J Acquir Immune Defic Syndr 2003 Oct 1; 34 (2): 243-5
81. Hazen R, Lanier ER. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 2003 Mar 1; 32 (3): 255-8
82. Rousseau FS, Wakeford C, Mommeja-Marin H, et al. Prospective randomised trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis 2003 Dec 1; 188 (11): 1652-8
83. Wiznia A, Violari A, Ndiweni D, et al. Once daily (QD) emtricitabine (FTC) with other antiretroviral agents (ART) in HIV-infected paediatric patients at 48 weeks [abstract no. TuPeB4431]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
84. McKinney R, Rodman J, Rathore M, et al. PACTG 1021: extended follow-up and pharmacokinetics for once daily emtricitabine, didanosine, and efavirenz for antiretroviral naive children and adolescents [abstract no. N.936]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA)
85. Bang LM, Scott LJ. Emtricitabine: an antiretroviral agent for HIV infection. Drugs 2003; 63 (22): 2413-24
86. Frampton JE, Perry CM. Emtricitabine: a review of its use in the management of HIV infection. Drugs 2005; 65 (10): 1427-48
87. Wang LH, Wiznia AA, Rathore MH, et al. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004 Jan; 48 (1): 183-91
88. Blum MR, Ndiweni D, Chittick G, et al. Steady state pharmacokinetic evaluation of emtricitabine in neonates exposed to HIV in utero [abstract no. N568]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-9; Denver (CO)
89. Saez-Llorens X, Violari A, Ndiweni D, et al. Once daily emtricitabine (FTC) in HIV-infected paediatric patients with other antiretroviral agents [abstract no. 872]. 10th Conference on Retroviral and Opportunistic Infections; 2003 Feb 10-14; Boston (MA)
90. Saag SM. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis 2006 Jan 1; 42 (1): 126-31
91. WHO expert working group meeting to determine preferred ARV medicines for treating and preventing HIV infection in younger children. Geneva. Oct 23-25, 2006. Meeting report [online]. Available from URL: http://www.who.int/hiv/ events/paediatricmeetingreport.pdf [Accessed 2007 Feb 16]
92. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004 Oct 1; 39 (7): 1038-46
93. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004 Apr 29; 350 (18): 1850-61
94. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004 Aug 15; 36 (5): 1011-9
95. Gibb D, Barry M, Ormesher S, et al. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. Br J Clin Pharmacol 1995 May; 39 (5): 527-30
96. Gallant JE, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004 Jul 14; 292 (2): 191-201
97. Blanco F, Garcia-Benayas T, Jose de la Cruz J, et al. First-line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin Trials 2003 Jan-Feb; 4 (1): 11-9
98. de Mendoza C, Ramos JT, Ciria L, et al. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. HIV Clin Trials 2002 Jan-Feb; 3 (1): 9-16
99. Hoggard PG, Kewn S, Barry MG, et al. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997 Jun; 41 (6): 1231-6
100. Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000 Jul; 182 (1): 321-5
101. Moyle GJ. Where now for Trizivir? Role of the triple-NRTI pill post-AACTG 5095. AIDS Read 2003 May; 13 (5): 223-4, 227, 244
102. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005 Dec 1; 192 (11): 1921-30
103. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults: a randomized equivalence trial. JAMA 2001; 285 (9): 1155-63
104. Kline MW, Fletcher CV, Harris AT, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr 1998 Mar; 132 (3 Pt 1): 543-6
105. Kearney BP, Sayre JR, Flaherty JF, et al. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol 2005; 45; 1360-7
106. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003 Dec 15; 37 (12): e174-6
107. Gathe J, Badaro R, Grimwood A, et al. Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir. J Acquir Immune Defic Syndr 2002 Dec; 31 (4): 399-403
108. Munderi P, on behalf of the DART trial team. Safety of nevirapine compared to abacavir on a background of zidovudine/lamivudine as first-line antiretroviral therapy: a randomised double-blind trial [abstract no. 109LB]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-9; Denver (CO)
109. DHHS panel on antiretroviral guidelines for adults and adolescents: a working group of the office of AIDS research advisory council. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [online]. Available from URL: http://www.AIDSinfo.nih.gov [Accessed 2006 Oct 10]
110. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision [online]. Available from URL: http://www.who.int/hiv/pub/guidelines/art/en/index.htm [Accessed 2007 Jun 1]
111. Hussain S, Khayat A, Tolaymat A, et al. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol 2006 Jul; 21 (7): 1034-6
112. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001; Oct 19; 15 (15): 1951-7
113. Giuliano M, Palmisano L, Galluzza C, et al. Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. AIDS 2003 Jul 4; 17 (10): 1570-2
114. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004 Jul 15; 351 (3): 229-40
115. Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000 Jan 28; 14 (2): F9-15
116. Melroy J, Nair V. The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS. Curr Pharm Des 2005; 11 (29): 3847-52
117. Deval J, Navarro JM, Selmi B, et al. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chem 2004 Jun 11; 279 (24): 25489-96
118. Sharma PL, Nurpeisov V, Lee K, et al. Replication-dependent 65R - >K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V. Virology 2004 Apr 10; 321 (2): 222-34
119. Haas DW. Pharmacogenomics and HIV therapeutics. J Infect Dis 2005 May 1; 191 (9): 1397-400
120. Law WP, Dore GJ, Duncombe CJ, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003 Oct 17; 17 (15): 2191-9
121. Moyle GJ. NNRTI choice: has 2NN changed our practice? AIDS Read 2003 Jul; 13 (7): 325-8
122. Aboulker JP, Babiker A, Chaix ML, et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004 Jan 23; 18 (2): 237-45
123. Kovacs A, Montepiedra G, Carey V, et al. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J Infect Dis 2005 Jul 15; 192 (2): 296-302
124. Green H, Gibb DM, Compagnucci A, et al. A randomised controlled trial of genotypic HIV drug resistance testing in HIV-1 infected children: the PERA (PENTA 8) trial. Antivir Ther 2006; 11 (7): 857-67
125. Ray AS, Yang Z, Shi J, et al. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Biochemistry 2002 Apr 23; 41 (16): 5150-62
126. Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS 2004 Aug 20; 18 (12): 1691-6
127. Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005 Jul 15; 41 (2): 236-42
128. Clinical advisory: important interim results from a phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095) [online]. Available from URL: http://www.nlm.nih.gov/databases/alerts/hiv.html [Accessed 1997 Feb 18]
129. Saavedra J, McCoig C, Mallory M, et al. Clinical experience with triple nucleoside (NRTI) combination ZDV/3TC/abacavir (ABC) as initial therapy in HIV-infected children [abstract no. 1941]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22-25; Chicago (IL)
130. Wells CJ, Sharland M, Smith CJ, et al. Triple nucleoside analogue therapy with zidovudine (AZT), lamivudine (3TC), and abacavir (ABC) in the paediatric HIV London South Network (PHILS-NET) cohort [abstract no. TuPeB4625]. XIV International AIDS Conference; 2002 Jul 7-12; Barcelona
131. Pensieroso S, Romiti ML, Palma P, et al. Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children. AIDS 2006 Sep 11; 20 (14): 1893-6
132. INITIO Trial International Co-ordinating Committee, Yeni P, Cooper DA, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006 Jul 22; 368 (9532): 287-98
133. Cozzi-Lepri A, De Luca A, Phillips AN, et al. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. J Infect Dis 2006 Jul 1; 194 (1): 20-8
134. Delaunay C, Brun-Vézinet F, Landman R, et al. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol 2005 Aug; 79 (15): 9572-8
135. Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr 2006 Nov 1; 43 (3): 284-92
136. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003 May 2; 17 (7): 987-99